Puff Up the Volume: Cannabis and the Teenage Brain

Genetic Engineering & Biotechnology News | January 15, 2019

Fourteen-year-olds who say they have smoked just one or two joints of marijuana in their lifetime demonstrate structural changes to multiple regions of their brains, according to the results of research by an international team of scientists across Europe and North America. “The implication is that this is potentially a consequence of cannabis use,” commented senior study author Hugh Garavan, Ph.D., a University of Vermont (UVM) professor of psychiatry. “You’re changing your brain with just one or two joints. Most people would likely assume that one or two joints would have no impact on the brain.”
The researchers said the findings, reported in The Journal of Neuroscience, warrant further study of cannabis use among adolescents. “Given the increasing levels of cannabis use amongst adolescents today, we suggest that studying the effects of recreational use early in life is an area of particular importance that should be addressed in the future by large scale, prospective studies,” they wrote in their published paper, which is titled, “Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence.”

Spotlight

GENEWIN Biotech has been established at Hosur, Tamil Nadu - India in 2007 which is recognized by Department of Biotechnology (DBT), under NCS-TCP, Ministry of Science and Technology, Government of India is one of the major producers of good quality and disease free plants on a large scale, 5 million per year through Tissue culture Techniques and sells at the lowest price throughout India. Tissue Culture is a technology used for mass propagation of elite and high yielding mother plants (through explants) that are carefully Virus Indexed which gives rise to disease free, uniform, genetically Pure and highly potential plants in large scale in the shortest period of time.
• Genewin Biotech awarded WORLD QUALITy COMMITMENT AWARD held at PARIS in October 2015 for its outstanding quality and its commitments towards customer service.

Spotlight

GENEWIN Biotech has been established at Hosur, Tamil Nadu - India in 2007 which is recognized by Department of Biotechnology (DBT), under NCS-TCP, Ministry of Science and Technology, Government of India is one of the major producers of good quality and disease free plants on a large scale, 5 million per year through Tissue culture Techniques and sells at the lowest price throughout India. Tissue Culture is a technology used for mass propagation of elite and high yielding mother plants (through explants) that are carefully Virus Indexed which gives rise to disease free, uniform, genetically Pure and highly potential plants in large scale in the shortest period of time.
• Genewin Biotech awarded WORLD QUALITy COMMITMENT AWARD held at PARIS in October 2015 for its outstanding quality and its commitments towards customer service.

Related News

MEDICAL

Nanoform Launches Technology that can form Biological Nanoparticles as Small as 50 nm and New Near-Term Business Target for 2021

Nanoform | November 27, 2020

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle formation technology gives want to improving the potential outcomes and probabilities of growing better medications for patients and it extends Nanoform's reach into the growing biological market. The technology is in its beginning phases of advancement and a patent application has recently been filed with the US Patent Office for the technology. As of today, Nanoform has two non-GMP lines on the biologics side notwithstanding the eight CESS® little atom nanoparticle innovation non-GMP lines.

Read More

CELL AND GENE THERAPY

PacBio Acquires Omniome, a DNA Sequencing Startup, for up to $800 Million

PacBio | July 26, 2021

Pacific Biosciences has had no trouble growing its business on its own in the year and a half since its acquisition by Illumina was blocked by the Federal Trade Commission due to concerns that the combination would establish a monopoly in DNA sequencing. Earlier this year, the sequencer manufacturer received a staggering $900 million investment from SoftBank—a commitment almost as large as the $1.2 billion promised by Illumina for the planned acquisition. PacBio is now making its acquisition, setting out a deal for up to $800 million to acquire Omniome, another provider of DNA sequencing technology. The majority of the transaction is comprised of planned upfront payments totaling about $600 million. This will be paid out in $300 million in cash and 9.4 million shares of PacBio common stock. The additional $200 million will come from milestone payments made when Omniome meets certain specified objectives, which will also be paid in a mix of cash and shares. PacBio has committed a small number of its current investors to a private issue of common stock to fund the acquisition. The total gross proceeds from this deal are expected to be about $300 million. Casdin Capital, SoftBank subsidiary SB Northstar LP, and T. Rowe Price Associates are among the investors who will buy approximately 11.2 million shares of PacBio stock for $26.75 per share, which is slightly less than the stock's closing price on the last full day of trading before the buyout was announced. PacBio will be able to extend the capabilities of its single-molecule, real-time sequencing technology, or SMRT Sequencing, for use by its clients in biomedical and infectious disease research, as well as therapeutic and diagnostic development, after the transaction is completed. PacBio's technology is based on long-read sequencing, which analyzes long strands of DNA at a time and can detect larger genomic variants and structural changes than short-read methods—though long-read sequencing has a higher potential error rate in those readings. Meanwhile, Omniome has created its short-read technology that concentrates on the proteins that bind to DNA to generate what it claims are more accurate analyses than existing short-read sequencers. Combining the two technologies is reminiscent of Illumina's planned acquisition of PacBio, which would have merged the latter's long-read technology with Illumina's short-read sequencing. The merger is a significant boost for Omniome, which has attracted several life sciences, investors since its inception in 2013. Each of its most two funding rounds—a series B in mid-2018 and a series C in early 2020—raised $60 million, bringing the San Diego-based startup's total funding to over $130 million.

Read More

MEDICAL

Moderna Announces Supply Agreement with UK Government for Additional 2 Million Doses of mRNA-1273, Moderna’s Vaccine Candidate Against Covid-19

Moderna | November 30, 2020

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to secure access to safe and effective COVID-19 vaccines by establishing a broad portfolio of the most promising vaccines. On November 16, Moderna reported that the autonomous, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 investigation of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

Read More